Introduction
Heart failure (HF) is a global epidemic in health care and a leading cause of mortality and morbidity worldwide (1) . Approximately 5.7 million individuals suffer from HF and over 550,000 are newly diagnosed as having HF every year in the United States (2) . The Heart Failure Prevalence and Predictors in Turkey (HAPPY) Study conducted in Turkey reported the prevalence of HF as 2.9% in the adult population, and estimated that 1 million adults suffer from HF symptoms (3) . Approximately 5% of all acute medical admissions are HF-related in Europe (4) . It has been stated that in 2006, 1 in 8.6 death reports in the United States mentioned HF (5) .
Besides its high prevalence and mortality rate, the disease places a huge economic burden on the health-care system. Heart failure hospitalization represents 1%-2% of all hospital admissions, which makes it the leading cause of hospitalization for patients older than 65 years (6) . The estimated direct and indirect costs of HF in the United States in 2010 were $39.2 billion in total (5) . The cost of HF care was reported to be two times higher than the cost of breast cancer and three times higher than the costs of colorectal cancer and lymphoma care in the USA (7) . The burden of HF has increased due to increasing elderly population as well as improved survival of patients with risks of HF such as acute myocardial infarction, hypertension, and diabetes mellitus.
In a study analyzing the annual global economic burden of HF in 197 countries, the overall economic cost of HF in 2012 was estimated as $108 billion per annum with direct costs accounting for ~60% ($65 billion) and indirect costs account-ABSTRACT ing for ~40% ($43 billion) of the overall spend (8) . A study by Heidenreich et al. (9) stated that by 2030, one of every 33 Americans, more than eight million individuals, will have HF and that total costs for HF in the 18-44 age group will increase from $1.51 billion to $2.48 billion, while the costs for the 65-79 age group will increase from $11.50 billion to $29.9 billion in 2030. In high-income countries, the economic burden of HF is high because it is associated with frequent hospital admissions (10, 11) . Heart failure currently accounts for approximately 5% of all emergency medical admissions to hospital (12) . In the USA, in 2008 the total inflation-adjusted cost of HF admissions was US$ 10.7 billion, compared with US$ 6.9 billion in 1997 (13) .
As HF admissions are expensive, reducing admissions, thereby reducing costs while improving the quality of life for patients with HF, is highly desirable. A retrospective costof-illness study conducted in a university hospital setting in Turkey in 2008 used in-hospital cost data from the records of patients who admitted to the hospital with angina pectoris, myocardial infarction, or HF and stated that HF was the second most costly disease (14) . It was reported that patients diagnosed with HF or myocardial infarction had significantly higher mean costs compared to patients with angina pectoris (14) . They calculated the daily cost of HF patients as 258 TL and the total cost per admission as 2351 TL (14) . These findings were very similar to a recent data based on expert panel views conducted in Turkey by Fak et al. (15) , where cost for HF was reported as 2435 TL per patient. When all these observations are taken into account, an up-to-date documentation of the cost of HF management considering both in-patient and outpatient source utilization in Turkey may help to demonstrate the economic burden of HF in actual clinical practice in Turkey. Thus, the present study was designed to analyze health-related cost of HF and to evaluate health-related source utilization for patients diagnosed with HF in Turkey.
Methods
The study used the Delphi process of seeking expert consensus of opinion and was conducted in 2015. A Delphi study is a structured process that invites experts to complete a series of 'rounds' to gather and refine information on the study question, until expert consensus is reached (16) . In the present study, the panel included 11 cardiologists experienced in HF, who are currently working at university hospitals (ten experts from seven institutions) or one from a training and research hospital in Turkey. The cities where these institutions are located are Ankara, İstanbul Eskişehir, Sivas, and Zonguldak.
Questionnaire forms
The standardized questionnaire form was prepared by an independent consultant under the supervision of an expert panelist representing the group. The questions were determined considering the cost items in the management of HF.
For this purpose, the literature data related to the subject and HF guidelines (i.e., Turkish Society of Cardiology HF Guideline, European Society of Cardiology HF Guideline, American Heart Association HF Guideline) were examined thoroughly. The questionnaire was prepared comprising the subjects included in these guidelines.
The questionnaire included items to reflect the opinion of the expert panelists on the distribution of the HF patients in terms of demographic and clinical characteristics (age, gender, level of ejection fraction, and New York Heart Association classification) and background disease states (hypertension, diabetes mellitus, coronary heart disease, valvular diseases, cardiomyopathies, and myocarditis). Costs related to out-patient follow-up (frequency of visits, consultations, medical tests), in-patient follow-up (emergency unit, intensive care unit, and other services), medications (in-patient and out-patient), and other therapies (invasive and non-invasive interventions) were also evaluated. The finalized questionnaire form was reviewed by one of the experts (ZO) and sent to the expert panelists via e-mail. The panelists were asked to send back the filled forms within 7 days. Then, an expert meeting was organized to review and finalize the answers given by the panelists.
As a principle set by the expert panel, the costs related with diagnosis, treatment, and follow-up of complications (rhythm abnormalities, cerebrovascular complications, renal complications, etc) or underlying pathologies (valvular disease, diabetes mellitus, etc) were not taken into account in the analysis, in order to avoid such cost items to be double-counted amongst possible several cost studies. This approach ensures that published costs of various disease states can be summed up to calculate the disease burden nationwide. Otherwise, simply adding the costs provided from various publications would lead to an over-estimation in the burden calculation.
For the estimation of utilization rate of medical devices per patient, including implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy-defibrillator (CRT-D), and cardiac resynchronization therapy-pacemaker (CRT-P), the annual numbers of devices sold throughout the country were divided by the estimated number of HF patients (data from HAPPY Study). These figures were then multiplied with the unit costs of ICD, CRT-D, or CRT-P. The expert panelists did not include CPAP (continuous positive airway pressure) and BiPAP (bi-level positive airway pressure) into the calculations, since the patients are supplied with these devices by SSI when needed, and the devices are given back when treatment is terminated. Thus, the net financial burden of these items to SGK can be neglected. Since the perspective of our analysis is SGK (i.e., we calculated the costs from the viewpoint of SGK), the costs of these devices are not included.
Statistical analysis
The analysis was performed from the perspective of reimbursement agency of Turkey (SGK). All data were analyzed Aras et al. The cost of heart failure management Anatol J Cardiol 2016; 16: 554-62 using descriptive statistics. The costs were provided in Turkish Lira (TL), and the cost model was based on the following equation: Cost=Σ (Frequency; %) X (Unit price; TL). Cost per day was calculated from the price lists stated in the Declaration of Health Care Implementation (SUT) published by Social Security Institute of Turkey (SSI).
Data were expressed with mean and minimum and maximum values.
Results

Basic characteristics
According to experts' view, the majority of the HF patients (34.1%) were in the age range of 60-69 years. Approximately 27.3% of the patients were ≥70 years old. Two-thirds of the patients were males (62.3%); 63.6% of the HF patients had reduced ejection fraction (HF-rEF), and 42.3% were in NYHA-II class (Table  1) . Coronary heart disease was the leading cause of HF (59.6%), and it was followed by cardiomyopathies (13.7%) ( Table 1) .
Follow-up data
According to experts' view, 75.9 % of the patients were followed up by a cardiology unit. The average annual number of out-patient visits was 3.64 for cardiology, 3.00 for the internal medicine, and 1.91 for the cardiovascular surgery clinics. Total annual number of visits weighted by branch was estimated as 3.41 (Table 2) . Out-patient management is assumed to be same in all HF patients, not differing with regard to preservation of left ventricular EF.
According to experts' view, 29.5% of HF patients admitted to the Emergency Unit with an average annual number of visits of 2.0. When all HF patients were considered, the annual number of visits was estimated to be 0.67. On the other hand, 40% of HF-rEF patients admitted to Emergency Unit with an annual number of visits of 2.0, and when all HF-rEF patients were considered, this figure was estimated to be 0.93 visits per year (Table 2) . (Table 3) .
Treatment
Beta blockers were the most commonly used drugs by the HF patients. The rate of beta blocker use was almost equal or even higher than renin-angiotensin system blocker use. The major medications used by HF patients were as follows: 75% beta blockers, 70% diuretics, 57% angiotensin-converting enzyme (ACE) inhibitors, 32% spironolactone, 20% angiotensin receptor blockers, and 20.5% digitalis (Table 4) . Chronic use of medications on out-patient basis is assumed to be same in all HF patients, not different between reduced or preserved EF. However, interventional treatments with devices were assumed to be used only in patients with HF-rEF. When all patients were considered, regardless of the degree of EF, the proportions of HF patients who need to be treated with interventional modalities are 8.4% for ICD, 5.5% for CRT-D, and 1.9% for CRT-P. These figures increased to 13.9% for ICD, 9.8% for CRT-D, and 4.0% for CRT-P in HF-rEF patients. Annual rates of interventional treatments were estimated to be one-fifth of these figures, since average life-time of these devices is about five years, and reimbursed once in every five years by national reimbursement agency (Table 4 for annual rates).
Unit costs
The unit cost of out-patient follow-up items and the cost of hospitalization including consultations, medical tests, medications and interventional treatments are given in Table 5 
Discussion
In the present analysis using the Delphi process, the estimations of an expert group on demographic and clinical characteristics of HF patients and cost of HF management were evaluated. The findings demonstrated the magnitude of the economic impact of HF management on Turkey's healthcare system.
Heart failure imposes both direct costs to healthcare systems and indirect costs to society through morbidity, unpaid care costs, premature mortality, and lost productivity. The cost resulting only from HF represents 2% of the total healthcare expenditure (17) . In a recent study analyzing the data of 197 countries (covering 98.7% of the world's population), the overall economic cost of HF in 2012 was estimated as $108 billion per annum (18) . Direct costs accounted for 60%, and indirect costs accounted for 40% of the overall spend (18) . The economic burden of HF results from its high prevalence, the demanding medical, device, and surgical therapies, the frequent comorbid conditions, and primarily from the frequent hospital admissions. The HAPPY Study conducted in Turkey reported the prevalence of HF as 2.9% in the adult population (3). The rapid aging of the population in developed countries, lack of a fall in incidence, and improving prognosis of HF are all acting to increase the number of people with chronic HF.
A recent meta-analysis using the published and unpublished data of nearly 240,000 hospitalizations for acute and chronic HF provided important data on the presentation, causes, management, and outcomes of HF in 31 low-and middle-income countries including Turkey (19) . According to their data, the mean age of the HF patients was 63 years (range: 42-77 years) being males 58% (95% CI: 54%-62%) of the patients. Across all low-and middle-income countries, the ischemic heart disease and hypertension were found to be the leading causes of HF. In line with these observations, our analysis demonstrated that 34% of HF patients were within the age range of 60-69 years, and 27% were ≥70 years old. According to our experts' view, 62% were males, and the ischemic heart disease was the leading cause of HF (60%). Heart failure is the most common reason for hospitalization in the elderly and exceeding a million admissions per year both in US and in Europe (20) (21) (22) . Despite therapeutic advances, the overall 5-year mortality rate remains approximately 50%. The prognosis of the syndrome is mainly driven by the poor outcome of patients hospitalized for HF. Readmission rates are quite high, reaching 30% during the first 3 months and exceeding 50% at 6 months post-discharge (22) . Overall, within a year after discharge, one third of patients are expected to die and two-thirds to be re-admitted because of HF (23) . In the United States, the annual HF-related expenses were calculated as $31 billion in 2012, and this cost is expected to rise to $97 billion in 2030 (24) . A study by Stewart et al. (10) estimated that 69% of the total expenditure related to HF results from hospitalizations, while drug therapy contributed to 18% of the cost. The direct mean cost of a single episode of hospital admission for HF in Europe lasting a median of 7 days has been calculated to €3200, an expenditure that represents only ward costs, laboratory tests, and drug therapies, excluding diagnostic or therapeutic interventions or hospitalization in Intensive Care Unit (25) .
Our analysis revealed that 32% of all HF patients and 43% of HF-rEF patients were estimated to be hospitalized with a hospital stay period of 6.77 days. A meta-analysis of HF care in low-and middle-income countries reported the average of stay in hospital as 10 days (18) . In a recent study by Ergene et al. (26) on chronic HF patients in a state hospital in Turkey, the average duration of hospitalization was found to be 7.0 days. Turkish Atherosclerosis Cost Study (2009), which provided data from five centers related with the hospitalizations due to HF in 2007, aPTT -activated partial thromboplastin time; BUN -blood urea nitrogen; CICU -cardiac intensive care unit; CK -creatine kinase; eGFR -estimated glomerular filtration rate; INR -international normalization ratio; NT-proBNP -N terminal pro brain natriuretic peptide; PT -prothrombin time *Most of the tests are included in out-patient visit package and CICU stay package. Therefore, the setting where the patient is followed at, is considered, whether to include or not the costs derived from these tests
reported the mean duration of hospitalization as 6.6 days, the total cost of stay as 1617 €, and daily cost of stay as 245 €/day (Unpublished data). On the other hand, the length of stay for HF patients reported by Sözmen et al. (14) and Ergin et al. (27) was 10.6 and 10 days, respectively. Average length of stay for HF was reported as 9.4 days in academic hospitals in Turkey (28) . In a previous study by Malki et al. (29) , the clinical presentation, hospital length of stay, and readmission in HF-pEF and HFrEF patients were evaluated, and it was reported that among consecutively hospitalized patients with HF, hospital length of stay and readmission rates within 6 months of discharge were not statistically different between patients with HF-pEF and HF-rEF. This finding was in accordance with the data of a national survey of HF in French hospitals demonstrating the length of hospital stay to be 11 days in both HF-pEF and HF-rEF patient groups (30) . These observations imply that HF-rEF patients do not have a markedly longer hospital stay in comparison to HF-pEF patients as the latter group are older and have more comorbidities in comparison to the former group. Thus, in our study, all cost analyses were performed considering the hospital stay to be same in both patient groups.
The one-year cost per congestive HF patient was established to be $3,802, based on an analysis of a state Medicaid dataset (31) with 52.1% of costs being related to prescriptions. Compared with other cardiovascular conditions among this Medicaid population, the annual cost per HF patient was found to be higher than the costs associated with diabetes or hypertension (31) .
A cost analysis study by Fak et al. (15) was based on identification of total costs related to management of acute coronary syndrome, HF, stroke, and the drug related adverse events in patients with atrial fibrillation, the average total cost of HF was reported as 4,524 TL (2,436 TL within the first month and 2,088 TL within a year excluding the first month) according to experts' view. In our analysis, the total annual cost of HF management was found to be 1,537 TL. In HF-rEF patient population, the calculated total annual cost was 2,141 TL. We demonstrated that the majority of the costs attributed to HF in this population was related to medication (435.37 TL/year) and out-patient follow-up (216.54 TL/year) when the diagnostic/ therapeutic interventions were excluded. The costs of diagnostic/therapeutic interventions and medications represented 42% and 20% of the total cost respectively. Medications used during the out-patient follow-up (336.94 TL/year) constituted the major component of all medication costs; the cost of inpatient medication was only 98.43 TL/year. The calculated costs of management (including hospitalization, consultations, and medical tests) in Emergency Unit, CICU, and medical ward were 126.93 TL/year, 192.22 TL/year, and 263.73 TL/year, respectively.
According to the results of the study by Sözmen et al. (14) , the total in-hospital cost of a HF patient per admission is 2.351 TL, and cost per day is 258 TL. They reported that unit cost regarding surgical interventions was the highest, followed by medical supplies, laboratory tests, and ward costs. They also found that patients diagnosed with HF or myocardial infarction had significantly higher mean costs compared to those with angina pectoris.
In the cost analysis by Ergene et al. (26) , the total cost of stay was 1,537 €, and average daily cost of stay was 221 €/day for HF patients in 2011. The retrospective cost-of-illness study conducted in a university hospital setting in Turkey in 2008 by Sözmen et al. (14) calculated the total cost of HF patients per admission as 2351 TL. The recent data based on expert panel views by Fak et al. (15) , reported the cost for HF as 2435 TL per patient.
The reason why our cost figures are lower than those reported in these earlier studies might be that the duration of hospital stay and costs are lower public hospitals compared to university hospitals. In addition to this, these variations may be due to the differences in the estimation of existing co-morbidities, and the cost of treating the co-morbidities. Although the majory of the HF patients (42%) were in NYHA-II class, 29% were in NYHA-III, and 10% were in NYHA-IV class. In general, mild HF patients visit their family physicians regularly more than a few times to get their prescriptions. On the other hand, the management of the severe cases should be considered as an additional factor to increase the cost. In addition to the direct costs, indirect, and societal costs of HF, which are not estimated in our study, may also influence the total cost of the patient. The number of patients with HF in 32,7 million Turkish population (of >35 years of age in 2014) could be calculated as 930 thousand, considering the prevalence of HF as 2.9% as reported in HAPPY study (3) . Thus, total annual national economic burden of HF has been calculated as 1,4 billion TL.
Study limitations
The study has some limitations. The major limitation is that the respondents may not be representative for "all" experts on HF, and the hospitals may not be representative of all regions in Turkey. These might limit the generalizability of the findings. Secondly, the results of this study only reflect current practice patterns. As healthcare technology and treatment guidelines change, the results are likely to become outdated.
Conclusion
To summarize, our findings reveal the extent of the economic burden of HF management on healthcare systems in our country. With the aging of the population, the impact of HF may increase. Thus, enhancing cardiovascular health strategies, new therapies, and improving implementation of existing preventative measures and therapies may be considered to improve the prevention and treatment of HF.
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